AAP: Investors give Starpharma $32m boost

AAP analyses how M&G’s investment will advance Starpharma’s research portfolio:  ‘A $32 million cash injection has given a boost to biotech Starpharma's plans to carry out advanced tests of a treatment for a common bacterial infection in women.

 

Go to the article (external link)

Starpharma completes A$32 million placement; SPP to follow

 Starpharma is pleased to announce it has successfully raised A$32 million via a placement to international and domestic institutional, sophisticated and professional investors.  It is intended to offer eligible existing shareholders the opportunity to also participate via a Share Purchase Plan to raise up to a further A$3 million.

AGM Chairman's address & CEO presentation; Results of AGM

Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 10th November 2011. Results of voting were released following the meeting.

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Quarterly Cash Flow Report for the period ended 30 September 2011.

ABC Radio Australia – Innovations: VivaGel Phase 3 Trial Gets Go-Ahead from FDA

ABC Radio Innovations Host Desley Blanch interviews Starpharma CEO Dr Jackie Fairley about the significance of Starpharma receiving FDA approval for the commencement of a Phase III clinical trial testing VivaGel for the treatment of Bacterial Vaginosis.

 

Go to the article (external link)


Starpharma secures FDA agreement on BV treatment Phase 3

Starpharma today announced that the Phase 3 clinical trial program for the VivaGel® bacterial vaginosis (BV) treatment program has been agreed with the US FDA following recent positive trial results and subsequent End of Phase 2 Meeting.

Ms Zita Peach appointed Non-Executive Director

Starpharma today announced the appointment of Ms Zita Peach as a Non-Executive Director.

Zita has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc.

Starpharma elevated to S&P/ASX300 index

Starpharma  has received notification that it will be elevated to the S&P/ASX 300 Index, effective from 19th September.

Starpharma Presents at Macquarie Investor Event

Starpharma is  one of two healthcare companies presenting at the Macquarie Bank Australia and New Zealand Annual Corporate Day in Hong Kong and Singapore.

Commencing today, the presentation to institutional investors from the Asia region will include 33 companies from Australia, from either the top 50 or 200 ASX listed companies.

Annual Report and Full Year Financial Results

Starpharma today released its annual report and financial results for the year ended 30 June 2011.

Financial Results

  • Cash position at end of year $18.9M
  • Net cash burn for the year $3.9M
  • Cash outflows from operations $6.5M
  • Reported loss $8.9M

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.